SecBot SecBot
PRESS-RELEASE ·Filed Jul 13, 2026

ANIP

ANI Pharmaceuticals, Inc.
BULLISH
Impact 6/10
Horizonmonths Processed4mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Monitor upcoming medical conference presentations (Q4 2026) for detailed data and any subsequent guidance updates. The results reinforce ILUVIEN's clinical value in chronic NIU-PS, potentially leading to increased prescription volume.

DirectionBullish
Confidencehigh
Horizonmonths

ILUVIEN

● Neutral Named in this press release
Impact
Phase
Approved (Phase 4 SYNCHRONICITY data reported July 2026)
Time to market
Already approved and marketed (FDA-approved September 2014 for DME; label expanded March 2025 for NIU-PS uveitis)
Next catalyst
None dated

What to watchILUVIEN is a steady commercial asset within ANI's larger Rare Disease transition story. The positive July 2026 Phase 4 SYNCHRONICITY data supports the uveitis label expansion's real-world use, but the stock's bigger drivers are Cortrophin Gel growth and overall margin expansion. Watch quarterly sales trends for ILUVIEN against the $78M-$83M 2026 guidance.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$81.08
T+0 close · Jul 13, 2026 · via day close
Latest settled
−11.79%
T+60 · $71.52
Vs SPY
−15.78%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 13 $81.08entry
  2. T+1 · 4mo ago −0.65%α −1.01% · $80.55
  3. T+5 · 4mo ago −2.32%α −1.53% · $79.20
  4. T+20 · 3mo ago −6.56%α −9.75% · $75.76
  5. T+60 · 7w ago −11.79%α −15.78% · $71.52
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ANI Pharmaceuticals reported positive topline Phase 4 data for ILUVIEN in chronic non-infectious uveitis affecting the posterior segment (NIU-PS), meeting both co-primary endpoints with statistical significance. The results support the drug's safety and efficacy in a real-world setting, potentially boosting commercial uptake.

Key Facts

  • SYNCHRONICITY trial met co-primary endpoints: mean change in BCVA (+3.6 letters, p<0.0077) and CST (-157.5 microns, p<0.0001) at 6 months.
  • Safety profile consistent with prior ILUVIEN trials; 29% treatment-related TEAEs, most common ocular hypertension (6%) and cataract (5%).
  • ILUVIEN already FDA-approved for DME (2014) and expanded for chronic NIU-PS (2025); this Phase 4 data adds real-world evidence.
  • Detailed results to be presented at medical conferences in Q4 2026.

Financial Impact

Positive data could drive increased adoption of ILUVIEN for chronic NIU-PS, supporting revenue growth from the Rare Disease segment, but no revenue guidance provided.

revenuemarket share

Risk Factors

  • Competition from other uveitis treatments; potential safety signals as real-world use expands.
  • Commercial execution risk in building out the rare disease sales force.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
92% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3326047

Track record

34 reports on ANIP

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +8.88% at T+60 after the Apr 8, 2026 report. 8 of 11 went positive at some point.

Filters
  1. Nov 18, 20263d ago Insider Cluster Neutral 2/10 Entry $69.13 Now $68.55 −0.84% settles Dec 18
  2. Nov 16, 20265d ago 144 Neutral 2/10 Entry $69.99 Now $68.55 −2.06% settles Dec 16
  3. Nov 16, 20266d ago 8-K Neutral 3/10 Entry $70.89 Now $68.55 −3.30% settles Dec 15
  4. Nov 9, 202612d ago Institutional Cluster Mixed 3/10 Entry $67.79 Now $68.55 +1.12% settles Dec 8
  5. Nov 5, 202616d ago 8-K Neutral 5/10 Entry $67.41 Now $68.55 +1.69% settles Dec 7
  6. Nov 5, 202617d ago 8-K Bullish 6/10 No price data
  7. Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
  8. Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
  9. Nov 5, 202617d ago Press Release Bullish 6/10 Entry $69.62 Now $68.55 −1.54% settles Dec 4
  10. Oct 29, 202623d ago 144 Neutral 2/10 Entry $72.00 Now $68.55 −4.79% settles Nov 30
Showing 10 of 34

US Market Status

Market Closed · Opens Mon (25h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 13, 2026